Analysts Set Savara Inc (NASDAQ:SVRA) Target Price at $9.86

Savara Inc (NASDAQ:SVRA) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $9.86.

Several equities analysts recently issued reports on SVRA shares. Wells Fargo & Company began coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Evercore ISI restated an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, HC Wainwright reduced their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Insider Transactions at Savara

In other Savara news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph S. Mccracken acquired 20,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average cost of $2.95 per share, with a total value of $59,000.00. Following the purchase, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 5.13% of the company’s stock.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. raised its stake in Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares during the period. Nantahala Capital Management LLC boosted its holdings in Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. Wellington Management Group LLP grew its position in Savara by 22.9% during the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares during the period. Vestal Point Capital LP increased its stake in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after acquiring an additional 1,600,000 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Savara by 17.5% in the 3rd quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock worth $28,547,000 after purchasing an additional 1,001,296 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Performance

NASDAQ:SVRA opened at $2.72 on Friday. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a fifty-two week low of $2.60 and a fifty-two week high of $5.70. The firm’s fifty day simple moving average is $3.16 and its 200-day simple moving average is $3.77. The stock has a market cap of $466.81 million, a PE ratio of -6.33 and a beta of 0.68.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). Analysts expect that Savara will post -0.45 earnings per share for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.